

United States Patent and Trademark Office

UNITED STATES DEFARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.usplo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/538,912	06/13/2005	Tatsuya Ohashi	050381	9528
23850 7590 10/09/2007 KRATZ, QUINTOS & HANSON, LLP 1420 K Street, N.W.			EXAMINER	
			GRUN, JAMES LESLIE	
Suite 400 WASHINGTO	N DC 20005		ART UNIT	PAPER NUMBER
WIDIMINGIO	151111101011, DC 20003		1641	
			MAIL DATE	DELIVERY MODE
		•	10/09/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)
•	10/538,912	OHASHI, TATSUYA
Office Action Summary	Examiner	Art Unit
	James L. Grun	1641
The MAILING DATE of this communication a	ppears on the cover sheet w	vith the correspondence address
Period for Reply		
 A SHORTENED STATUTORY PERIOD FOR REP WHICHEVER IS LONGER, FROM THE MAILING Extensions of time may be available under the provisions of 37 CFR after SIX (6) MONTHS from the mailing date of this communication. If NO period for reply is specified above, the maximum statutory period Failure to reply within the set or extended period for reply will, by state Any reply received by the Office later than three months after the mail earned patent term adjustment. See 37 CFR 1.704(b). 	DATE OF THIS COMMUN 1.136(a). In no event, however, may a od will apply and will expire SIX (6) MO ute, cause the application to become A	ICATION. reply be timely filed NTHS from the mailing date of this communication. BANDONED (35 U.S.C. § 133).
Status		
1) Responsive to communication(s) filed on 13	June 2005.	
•	nis action is non-final.	•
3) Since this application is in condition for allow	vance except for formal mat	ters, prosecution as to the merits is
closed in accordance with the practice under	r <i>Ex parte Quayle</i> , 1935 C.I	D. 11, 453 O.G. 213.
Disposition of Claims		
• 4)⊠ Claim(s) <u>1-16</u> is/are pending in the application	on.	
4a) Of the above claim(s) is/are withdo		
5) Claim(s) is/are allowed.		
6) Claim(s) is/are rejected.		•
7) Claim(s) is/are objected to.		
8) Claim(s) <u>1-16</u> are subject to restriction and/o	or election requirement.	•
Application Papers	·	
9) The specification is objected to by the Exami	ner.	
10) The drawing(s) filed on is/are: a) a		by the Examiner.
Applicant may not request that any objection to the	•	<u>.</u>
Replacement drawing sheet(s) including the corre		<u>-</u>
11) The oath or declaration is objected to by the	Examiner. Note the attache	d Office Action or form PTO-152.
Priority under 35 U.S.C. § 119		
12) Acknowledgment is made of a claim for foreign	an priority under 35 U.S.C.	§ 119(a)-(d) or (f).
a) ☐ All b) ☐ Some * c) ☐ None of:	g., p.,,	
1. Certified copies of the priority docume	nts have been received.	
2. Certified copies of the priority docume	nts have been received in A	Application No
3. Copies of the certified copies of the pr	iority documents have beer	n received in this National Stage
application from the International Bure	, , , , ,	
* See the attached detailed Office action for a list	st of the certified copies no	t received.
	•	
Attachment(s)		
1) Motice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	•	Summary (PTO-413) (s)/Mail Date
3) Information Disclosure Statement(s) (PTO/SB/08)	5) Notice of	Informal Patent Application
Paper No(s)/Mail Date	6)	· .

Application/Control Number: 10/538,912

Art Unit: 1641

In the examination of international applications filed under the Patent Cooperation Treaty, PCT Rule 13.1 states that the "international application shall relate to one invention only or to a group of inventions so linked as to form a single general inventive concept ('requirement of unity of invention')".

The method for determining unity of invention under PCT Rule 13 shall be construed as permitting, in particular, the inclusion of any one of the following combinations of claims of different categories in the same international application:

- (1) in addition to an independent claim for a given product, an independent claim for a process specially adapted for the manufacture of said product, and an independent claim for a use of said product, or
- (2) in addition to an independent claim for a given process, an independent claim for an apparatus or means specifically designed for carrying out said process, or
- (3) in addition to an independent claim for a given product, an independent claim for a process specially adapted for the manufacture of said product, and an independent claim for an apparatus or means specifically designed for carrying out the process.

Unity of invention is fulfilled only when a group of inventions is linked in technical relationship by at least one corresponding technical feature (i.e. the inventions are not independent), wherein the corresponding technical feature(s)is(are) "special" under PCT Rule 13.2, i.e. a contribution over the prior art.

This application contains inventions or groups of inventions that are not so linked as to form a single inventive concept. Under PCT Rule 13 the following combinations of claims of different categories are permissible and restriction to one of the following combinations is required:

- I. Claims 1-11 and 13-16, drawn to a given product (antibodies), a process using said product (immunoassay method), and an apparatus or means specifically designed for carrying out said process (kit).
 - II. Claim 12, drawn to a given product (marker molecule protein fragments).

The inventions listed as Groups I-II do not meet the requirements for Unity of Invention for the following reasons:

Application/Control Number: 10/538,912

Art Unit: 1641

1. The reference of Janckila et al. (Clinical Chem. <u>47</u>: 74, 2001) appears to teach antibodies and their use as claimed. Therefore, the claimed inventions share no "special" technical feature.

2. The antibody products of Group I are not linked in technical relationship with the protein fragment products of Group II because these independent products share no corresponding technical feature. The antibody products are not a "special" technical feature, as set forth above, and the protein fragment and antibody products share no common structure, function, or use and are not related by being required for the making or use of the other. For example, the protein fragments are not required for the elicitation of the antibodies or for any methods using the antibodies and the antibodies are unrelated to the generation or use of the protein fragments.

Applicant is advised that the reply to this requirement to be complete <u>must</u> include (i) an election of a invention to be examined even though the requirement may be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse. Traversal must be presented at the time of election in order to be considered timely. Failure to timely traverse the requirement will result in the loss of right to petition under 37 CFR 1.144. If claims are added after the election, applicant must indicate which of these claims are readable on the elected invention.

Art Unit: 1641

Should applicant traverse on the ground that the inventions are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 C.F.R. 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a diligently-filed petition under 37 C.F.R. 1.48(b) and by the fee required under 37 C.F.R. 1.17(h).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to James L. Grun, Ph.D., whose telephone number is (571) 272-0821. The examiner can normally be reached on weekdays from 9 a.m. to 5 p.m.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Long Le, SPE, can be contacted at (571) 272-0823.

The phone number for official facsimile transmitted communications to TC 1600, Group 1640, is (571) 273-8300.

Any inquiry of a general nature or relating to the status of this application, or requests to supply missing elements from Office communications, should be directed to the Group receptionist whose telephone number is (571) 272-1600.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

/JLG/

James L. Grun, Ph.D. October 1, 2007

LONG V. LE 1981/07
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600